Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors

NCT00333502 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT00333502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00333502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2006
Completion date
April 30, 2012
Enrollment
62 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumor